Conjugates for treating diseases caused by PSMA expressing cells
US10912840B2 · kind B2 · utility
3Cited by
124References
5Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | May 11, 2018 |
| Grant date | Feb 9, 2021 |
| Priority date | — |
| Expiry date | Aug 14, 2038 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61K38/00
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The invention described herein pertains to the diagnosis, imaging, and/or treatment of pathogenic cell populations. In particular, the invention described herein pertains to the diagnosis, imaging, and/or treatment of diseases caused by PSMA expressing cells, such as prostate cancer cells, using compounds capable of targeting PSMA expressing cells.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.